Abstract
Breast carcinoma is one of the leading causes of mortality among female cancers globally. Heparan sulfate proteoglycans, found predominantly on cell surfaces and in the extracellular matrix, are known to regulate breast cancer cellular behavior. Many studies have shown that these molecules serve as potential biomarkers for breast cancer. In addition, they have aberrant expression patterns and participate in various molecular signaling pathways in tumor progression. There is substantial interest in targeting heparan sulfate proteoglycans for cancer treatment, which needs to be tailored according to the roles that each proteoglycan plays in cancer biology. Current clinical trials using phosphomannopentaose sulfate, a heparan sulfate mimic, and various forms of heparin have produced promising results in breast cancer patients. Besides heparan sulfate chains, novel therapeutic agents could potentially be developed to regulate the proteoglycan core proteins as well as enzymes that modify heparan sulfation patterns. This review discusses the current use and future prospective applications of heparan sulfate proteoglycans, which have been recently patented, as therapeutic targets in breast cancer treatment.
Keywords: Breast cancer, heparan sulfate, heparin, syndecan, glypican, glycosaminoglycans, proteoglycans, phosphomannopentaose sulfate, endosulfatase, heparanase
Recent Patents on Anti-Cancer Drug Discovery
Title: Targeting Heparan Sulfate Proteoglycans in Breast Cancer Treatment
Volume: 3 Issue: 3
Author(s): Chuay-Yeng Koo, Yin-Ping Sen, Boon-Huat Bay and George W. Yip
Affiliation:
Keywords: Breast cancer, heparan sulfate, heparin, syndecan, glypican, glycosaminoglycans, proteoglycans, phosphomannopentaose sulfate, endosulfatase, heparanase
Abstract: Breast carcinoma is one of the leading causes of mortality among female cancers globally. Heparan sulfate proteoglycans, found predominantly on cell surfaces and in the extracellular matrix, are known to regulate breast cancer cellular behavior. Many studies have shown that these molecules serve as potential biomarkers for breast cancer. In addition, they have aberrant expression patterns and participate in various molecular signaling pathways in tumor progression. There is substantial interest in targeting heparan sulfate proteoglycans for cancer treatment, which needs to be tailored according to the roles that each proteoglycan plays in cancer biology. Current clinical trials using phosphomannopentaose sulfate, a heparan sulfate mimic, and various forms of heparin have produced promising results in breast cancer patients. Besides heparan sulfate chains, novel therapeutic agents could potentially be developed to regulate the proteoglycan core proteins as well as enzymes that modify heparan sulfation patterns. This review discusses the current use and future prospective applications of heparan sulfate proteoglycans, which have been recently patented, as therapeutic targets in breast cancer treatment.
Export Options
About this article
Cite this article as:
Koo Chuay-Yeng, Sen Yin-Ping, Bay Boon-Huat and Yip W. George, Targeting Heparan Sulfate Proteoglycans in Breast Cancer Treatment, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (3) . https://dx.doi.org/10.2174/157489208786242278
DOI https://dx.doi.org/10.2174/157489208786242278 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Approaches to Chronic Spinal Cord Injury
Current Pharmaceutical Design HER2 in the Era of Molecular Medicine: A Review
Current Cancer Therapy Reviews (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) The Role of MDR1 Genetic Polymorphisms in Interindividual Variability in P-glycoprotein Expression and Function
Current Drug Metabolism Nutraceuticals and "Repurposed" Drugs of Phytochemical Origin in Prevention and Interception of Chronic Degenerative Diseases and Cancer
Current Medicinal Chemistry Therapeutic Targets for Management of Periodontitis and Diabetes
Current Pharmaceutical Design Current Status and Future of Target-Based Therapeutics
Current Cancer Drug Targets Current Status of CT Colonography
Current Medical Imaging The Complexity of DEK Signaling in Cancer Progression
Current Cancer Drug Targets Toll-Like Receptor (TLR) Response Tolerance: A Key Physiological “ Damage Limitation ” Effect and an Important Potential Opportunity for Therapy
Current Medicinal Chemistry The Synthesis and Anticancer Potentials of Quinoline Analogues: A Review of Literature
Mini-Reviews in Organic Chemistry Garlic (<i>Allium sativum</i> L.): Its Chemistry, Nutritional Composition, Toxicity, and Anticancer Properties
Current Topics in Medicinal Chemistry Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside
Current Pharmaceutical Design New Insights on Fak and Fak Inhibitors
Current Medicinal Chemistry Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Biological Activities of QIAPI 1 as a Melanin Precursor and Its Therapeutic Effects in Wistar Rats Exposed to Arsenic Poisoning
Central Nervous System Agents in Medicinal Chemistry Gold Nanostructure: Fabrication, Surface Modification, Targeting Imaging, and Enhanced Radiotherapy
Current Nanoscience Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Adhesion Molecules as Targets for the Treatment of Neoplastic Diseases
Current Pharmaceutical Design Tubulin-based Structure-affinity Relationships for Antimitotic Vinca Alkaloids
Anti-Cancer Agents in Medicinal Chemistry DNA Microarray-Based Gene Expression Profiling in Cancer: Aiding Cancer Diagnosis, Assessing Prognosis and Predicting Response to Therapy
Current Pharmacogenomics